Ligand Pharmaceuticals Incorporated announced that its partner Viking Therapeutics, Inc. announced positive top-line results from its Phase 2b clinical trial of VOYAGE, a novel liver-selective thyroid. | May 17, 2023
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival. | May 3, 2023
First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023
At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo 62% of patients treated with TEPEZZA had. | April 10, 2023